The U.S. government’s Medicare program on January 11 said it plans to cover Alzheimer’s treatments including Biogen Inc.’s Aduhelm, with some conditions.

Researchers at Emory investigated the use of an FDA-approved ADHD medication on patients with mild Alzheimer’s symptoms and found it appeared to reduce levels of tau.

Biogen announced that effective January 1, 2022, the company will cut the wholesale acquisition cost of the Alzheimer’s drug Aduhelm (aducanumab) in half.

BioSpace reviewed some of the more interesting scientific studies recently published, including research into a potential cause of Alzheimer’s disease and how deleting dysfunctional fat cells could alleviate diabetes.

With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened during 2021. And there are many! The accomplishments, opportunities and possibilities the scientific community has brought to bear, providing a way out of the COVID-19 pandemic and hope for the future of meaningful therapies for several challenging diseases, deserve a major shout-out.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative trend vote on the Marketing Authorization Application for Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab).

As Biogen continues to struggle with the fallout from the controversial approval of the Alzheimer’s drug Aduhelm, the company’s head of research and development will step down at the end of 2021.

Biogen Inc.’s Aduhelm – approved by U.S. regulators during 2020 for the ability of the Alzheimer’s drug to reduce amyloid brain plaques – also lowers levels of a second protein that accumulates in the brains of people with the disease, according to new data released by the company on November 11.

AC Immune’s stock fell 9 percent on the news that the company’s Phase II Lauriet study of the investigational anti-Tau monoclonal antibody semorinemab in mild-to-moderate Alzheimer’s disease (AD) did not meet all endpoints.

Several studies point to promising new approaches to treating and preventing Alzheimer’s disease and a deeper understanding of how the disease progresses.